@article{10.37349/etat.2024.00274,
abstract = {Upper tract urothelial cancer (UTUC) are rare subsets of urothelial cancer, which typically present with more aggressive course. Molecular markers stratifying urothelial tumors as luminal subtype and non-luminal subtype tumors have been proposed to select patients who may have greater or lesser benefit from neoadjuvant systemic therapy in bladder cancer, though not yet evaluated in UTUC. Here, a single-institution study retrospectively obtained clinical and genomic information in patients with UTUC and evaluated four patient tumors using the Decipher Bladder® assay and Foundation Medicine® test. All four patients had non-luminal molecular subtype including basal (N = 4) and mixed basal/claudin-low (N = 2) subtypes. The best clinical response achieved was stable disease in a patient who had basal/claudin-low subtype with residual ypT3 after neoadjuvant chemotherapy. For the remaining three patients, all were treated with platinum-based chemotherapy for eventual metastatic disease but all three showed progressive disease with limited overall survival, highlighting their aggressive course. The non-luminal subtype and lack of FGFR alteration may partly explain the poor overall outcomes while the real-world benefit of next generation sequencing for clinical use in UTUC patients require further clarification in a larger cohort study.},
author = {Hwang, Min Woo and Kauffeld, Jasmine and Belay, Sarah and {De Jong}, Joep J. and Davicioni, Elai and Li, Wenping and Aragon-ching, Jeanny B.},
doi = {10.37349/etat.2024.00274},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {1261--1270},
title = {{Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002274},
volume = {5},
year = {2024},
number = {6}
}